AJANTPHARMPharmaceuticals
Ajanta Pharma Ltd — Cash Flow Statement
₹2805.10
-2.50%
Ajanta Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 839.31 Cr | 632.66 Cr | 617.62 Cr | 412.87 Cr | — |
| Repurchase Of Capital Stock | -351.34 Cr | -388.27 Cr | -1.44 Cr | -285.59 Cr | — |
| Issuance Of Capital Stock | 0.01 Cr | 0.00 | 0.00 | — | — |
| Capital Expenditure | -317.92 Cr | -152.41 Cr | -174.49 Cr | -148.84 Cr | — |
| End Cash Position | 176.79 Cr | 129.23 Cr | 330.67 Cr | 205.41 Cr | — |
| Beginning Cash Position | 129.49 Cr | 329.83 Cr | 206.36 Cr | 177.51 Cr | — |
| Changes In Cash | 47.30 Cr | -200.60 Cr | 124.31 Cr | 27.90 Cr | — |
| Financing Cash Flow | -733.41 Cr | -1.05K Cr | -108.20 Cr | -459.71 Cr | — |
| Net Other Financing Charges | -1.61 Cr | -0.92 Cr | -1.11 Cr | -68.19 Cr | — |
| Interest Paid Cff | -17.31 Cr | -3.53 Cr | -2.33 Cr | -7.35 Cr | — |
| Cash Dividends Paid | -349.37 Cr | -642.17 Cr | -89.69 Cr | -82.21 Cr | — |
| Net Common Stock Issuance | -351.33 Cr | -388.27 Cr | -1.44 Cr | -285.59 Cr | — |
| Common Stock Payments | -351.34 Cr | -388.27 Cr | -1.44 Cr | -285.59 Cr | — |
| Common Stock Issuance | 0.01 Cr | 0.00 | 0.00 | — | — |
| Net Issuance Payments Of Debt | 1.10 Cr | 0.06 Cr | -0.49 Cr | 0.23 Cr | — |
| Net Long Term Debt Issuance | 1.10 Cr | 0.06 Cr | -0.49 Cr | 0.23 Cr | — |
| Investing Cash Flow | -376.52 Cr | 65.39 Cr | -559.60 Cr | -74.10 Cr | — |
| Net Other Investing Changes | 44.08 Cr | 27.00 Cr | 0.52 Cr | 0.90 Cr | — |
| Net Investment Purchase And Sale | -97.57 Cr | 177.42 Cr | -386.36 Cr | 55.46 Cr | — |
| Sale Of Investment | 2.66K Cr | 2.26K Cr | 1.28K Cr | 1.09K Cr | — |
| Purchase Of Investment | -2.76K Cr | -2.08K Cr | -1.66K Cr | -1.04K Cr | — |
| Net Business Purchase And Sale | -6.25 Cr | 0.00 | — | — | — |
| Purchase Of Business | -6.25 Cr | 0.00 | — | — | — |
| Net PPE Purchase And Sale | 1.14 Cr | 13.38 Cr | 0.73 Cr | 18.38 Cr | — |
| Sale Of PPE | 1.14 Cr | 13.38 Cr | 0.73 Cr | 18.38 Cr | — |
| Capital Expenditure Reported | -317.92 Cr | -152.41 Cr | -174.49 Cr | -148.84 Cr | — |
| Operating Cash Flow | 1.16K Cr | 785.07 Cr | 792.11 Cr | 561.71 Cr | — |
| Taxes Refund Paid | -322.97 Cr | -312.13 Cr | -151.29 Cr | -239.13 Cr | — |
| Change In Working Capital | 178.93 Cr | -99.78 Cr | 66.85 Cr | -200.39 Cr | — |
| Change In Payable | 107.19 Cr | 97.61 Cr | 96.91 Cr | -48.02 Cr | — |
| Change In Inventory | -74.51 Cr | -12.30 Cr | -22.37 Cr | -25.66 Cr | — |
| Change In Receivables | 105.77 Cr | -201.70 Cr | -21.57 Cr | -268.02 Cr | — |
| Other Non Cash Items | -23.68 Cr | -20.12 Cr | 5.51 Cr | 9.87 Cr | — |
| Stock Based Compensation | 3.88 Cr | 5.49 Cr | 0.22 Cr | 0.30 Cr | — |
| Depreciation And Amortization | 144.11 Cr | 135.40 Cr | 130.80 Cr | 125.30 Cr | — |
| Amortization Cash Flow | 8.22 Cr | 5.01 Cr | 4.10 Cr | 3.94 Cr | — |
| Depreciation | 135.89 Cr | 130.39 Cr | 126.70 Cr | 121.36 Cr | — |
| Gain Loss On Investment Securities | -2.52 Cr | -24.83 Cr | 3.48 Cr | -30.38 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -10.31 Cr | -9.42 Cr | -14.08 Cr | -21.19 Cr | — |
| Gain Loss On Sale Of PPE | 0.60 Cr | -3.49 Cr | 6.19 Cr | 3.87 Cr | — |
| Net Income From Continuing Operations | 1.19K Cr | 1.11K Cr | 745.25 Cr | 909.48 Cr | — |
| Change In Other Current Liabilities | — | 73.34 Cr | -32.38 Cr | 91.75 Cr | 45.06 Cr |
| Change In Other Current Assets | — | -22.82 Cr | 40.49 Cr | 48.71 Cr | -29.13 Cr |
| Repayment Of Debt | — | — | -0.49 Cr | — | — |
| Long Term Debt Payments | — | — | -0.49 Cr | — | — |
| Issuance Of Debt | — | — | — | 0.23 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | — | — | -239.13 Cr | 0.01 Cr |
| Long Term Debt Issuance | — | — | — | 0.23 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ajanta Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.